Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
The New England journal of medicine 2018 04 16() doi 10.1056/NEJMoa1716078 Abstract Background Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non-small-cell lung cancer (NSCLC)...
Read More